Analysis of the Emerging Disease Landscape - COVID-19 - April 2020

Summary

The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.

Scope

• Global epidemiology metrics and trends
• Snapshot of epidemiological trends to date in the top three most-affected countries
• An overview of the pipeline for antivirals and vaccines
• Summary of available efficacy data
• An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
• Highlights in deal-making trends, particularly public-private partnerships
• Spotlight on social media coverage

Reasons to Buy

• Understand the global epidemiology of COVID-19
• Obtain a snapshot of epidemiological trends to date in the top three most-affected countries
• Access an overview of the pipeline for therapeutics and vaccines
• Stay up to date on available efficacy data for pipeline-stage products
• View the clinical trials landscape by across key attributes
• Get up to speed on highlights in deal-making trends, particularly public-private partnerships
• Monitor top trends in social media coverage